• In May 2026, Guardant Health announced that its FDA-approved Shield blood test was added to updated American Cancer Society colorectal cancer screening guidelines as a blood-based option for average-risk adults 45 and older who decline or do not complete traditional tests.
• This guideline inclusion, alongside recent FDA clearance of the expanded Guardant360 Liquid CDx panel, highlights growing clinical recognition of Guardant’s blood-based cancer diagnostics across both screening and treatment decision workflows.
• Next, we’ll examine how Shield’s new American Cancer Society guideline status could influence Guardant Health’s existing investment narrative and risk profile.

The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Guardant Health Investment Narrative Recap

To own Guardant Health, you need to believe blood based cancer screening and treatment decision tools can support a much larger business over time, despite current losses and heavy cash burn. The ACS endorsement of Shield strengthens the core thesis around guideline driven adoption and may ease one major risk around Shield uptake, but it does not remove near term concerns over high spending, negative free cash flow, and potential future dilution.

The most relevant recent announcement here is the FDA approval of Guardant360 Liquid CDx, which extends Guardant’s presence in treatment selection while Shield moves further into frontline screening. Together, these updates reinforce the idea that Guardant is building a unified blood based oncology platform with touchpoints from early detection to therapy matching, but they also concentrate execution and reimbursement risk in a few highly visible products.

Yet investors should also be aware that growing ACS backed Shield volumes could amplify the impact if reimbursement terms or pricing were to weaken over time...

Guardant Health's narrative projects $2.1 billion revenue and $105.5 million earnings by 2029.

Uncover how Guardant Health's forecasts yield a $128.33 fair value, in line with its current price.

Exploring Other Perspectives

Some analysts were already far more optimistic, assuming Guardant could reach about US$2.3 billion of revenue and US$123.6 million of earnings by 2028, so Shield’s ACS upgrade might either support that bullish view or force a rethink if reimbursement or pricing risks start to look more pressing.

Explore 6 other fair value estimates on Guardant Health - why the stock might be worth as much as 62% more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Guardant Health research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Guardant Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Guardant Health's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Explore 29 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
• We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.